October 20, 2014 / 2:12 PM / 3 years ago

INTERVIEW-Valeant CEO sees revised Allergan bid worth more than $200 per share

Oct 20 (Reuters) - Valeant Pharmaceuticals Inc Chief Executive Michael Pearson said in an interview with Reuters on Monday that he is confident a revised bid for Allergan Inc will be worth over $200 per share, once Valeant's stock rises and with cash added to the offer.

Pearson said Valeant could make a revised offer at any time and that the company's stock has been hurt by Allergan's criticism and uncertainty about whether a deal will get done. Valeant's offer is currently worth about $176 per share. (Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Chizu Nomiyama)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below